Literature DB >> 21947347

Association of the MDR1 3435 polymorphism in patients with refractory rheumatoid arthritis in a Chinese population.

Jinwei Chen1, Lixiao Chen, Ni Mao, Yiming Liu.   

Abstract

To evaluate whether the multidrug resistance gene 1 (MDR1) exon 26 polymorphisms are associated with the refractory rheumatoid arthritis (RRA). The study was carried out on two hundred and twenty-three patients with RA treated and one hundred and three normal controls. The RA treated were divided into two groups according the response to disease-modifying antirheumatic drugs (DMARDs). There were 108 patients in the effective group and 115 patients in the ineffective group. Genotypes of the C3435T polymorphism were determined by polymerase chain reaction followed by restriction digestion (PCR-RFLP). There were significant differences in the genotype frequency and allele frequency among three groups. Compared to responders and controls, the nonresponders carried more CC genotype (χ(2) = 5.306, P = 0.021; χ(2) = 7.810, P = 0.005) and more C allele (χ(2) = 6.601, P = 0.010; χ(2) = 12.172, P = 0.000). But, there were no statistically significant differences in genotype nor allele frequency between RA and healthy controls. The results from our study suggest that the C3435T MDR1 gene polymorphism may not be related with the RA susceptibility, but may influence the efficacy of RA therapy with DMARDs, and the 3435CC genotype may be related with RRA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21947347     DOI: 10.1007/s00296-011-2088-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  13 in total

1.  Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene.

Authors:  M Tanabe; I Ieiri; N Nagata; K Inoue; S Ito; Y Kanamori; M Takahashi; Y Kurata; J Kigawa; S Higuchi; N Terakawa; K Otsubo
Journal:  J Pharmacol Exp Ther       Date:  2001-06       Impact factor: 4.030

2.  Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part I: Increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome.

Authors:  L Llorente; Y Richaud-Patin; A Díaz-Borjón; C Alvarado de la Barrera; J Jakez-Ocampo; H de la Fuente; R Gonzalez-Amaro; E Diaz-Jouanen
Journal:  Joint Bone Spine       Date:  2000-01       Impact factor: 4.929

Review 3.  The use of single-nucleotide polymorphism maps in pharmacogenomics.

Authors:  J J McCarthy; R Hilfiker
Journal:  Nat Biotechnol       Date:  2000-05       Impact factor: 54.908

4.  Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability.

Authors:  Danxin Wang; Andrew D Johnson; Audrey C Papp; Deanna L Kroetz; Wolfgang Sadée
Journal:  Pharmacogenet Genomics       Date:  2005-10       Impact factor: 2.089

5.  Monoclonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes.

Authors:  G Raghu; S W Park; I B Roninson; E B Mechetner
Journal:  Exp Hematol       Date:  1996-08       Impact factor: 3.084

6.  Identification of functionally variant MDR1 alleles among European Americans and African Americans.

Authors:  R B Kim; B F Leake; E F Choo; G K Dresser; S V Kubba; U I Schwarz; A Taylor; H G Xie; J McKinsey; S Zhou; L B Lan; J D Schuetz; E G Schuetz; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  2001-08       Impact factor: 6.875

7.  MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity.

Authors:  M M Ameyaw; F Regateiro; T Li; X Liu; M Tariq; A Mobarek; N Thornton; G O Folayan; J Githang'a; A Indalo; D Ofori-Adjei; D A Price-Evans; H L McLeod
Journal:  Pharmacogenetics       Date:  2001-04

8.  Establishment of multidrug-resistance cell line C(6)/adr and reversal of drug-resistance.

Authors:  Fusheng Liu; Chongcheng Wang; Qinglin Zhang; Junhua Li; Yazhuo Zhang
Journal:  Chin Med J (Engl)       Date:  2002-02       Impact factor: 2.628

Review 9.  Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein).

Authors:  Serena Marchetti; Roberto Mazzanti; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2007-08

10.  Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis.

Authors:  S Tsujimura; K Saito; M Nawata; S Nakayamada; Y Tanaka
Journal:  Ann Rheum Dis       Date:  2007-07-27       Impact factor: 19.103

View more
  6 in total

1.  P-glycoprotein gene MDR1 polymorphisms and susceptibility to systemic lupus erythematosus in Guangxi population: a case-control study.

Authors:  Jian Wang; Yanqiong Liu; Jiangyang Zhao; Juanjuan Xu; Shan Li; Xue Qin
Journal:  Rheumatol Int       Date:  2017-02-02       Impact factor: 2.631

2.  MDR1 gene polymorphisms are associated with glucocorticoid-induced avascular necrosis of the femoral head in a Chinese population.

Authors:  Yun Xue; Zhan-Qin Zhao; Dun Hong; Hong-Jun Zhang; Hai-Xiao Chen; Shun-Wu Fan
Journal:  Genet Test Mol Biomarkers       Date:  2014-01-04

3.  No correlation between MTHFR c.677 C > T, MTHFR c.1298 A > C, and ABCB1 c.3435 C > T polymorphisms and methotrexate therapeutic outcome of rheumatoid arthritis in West Algerian population.

Authors:  Wefa Boughrara; Ahmed Benzaoui; Meriem Aberkane; Fatima Zohra Moghtit; Samia Dorgham; Aicha Sarah Lardjam-Hetraf; Hadjer Ouhaibi-Djellouli; Elisabeth Petit Teixeira; Abdallah Boudjema
Journal:  Inflamm Res       Date:  2017-03-15       Impact factor: 4.575

4.  Multidrug resistance 1 (MDR1) 3435C>T gene polymorphism influences the clinical phenotype and methotrexate-induced adverse events in South Indian Tamil rheumatoid arthritis.

Authors:  Niveditha Muralidharan; Paul T Antony; Vikramraj K Jain; Christina Mary Mariaselvam; Vir Singh Negi
Journal:  Eur J Clin Pharmacol       Date:  2015-06-14       Impact factor: 2.953

Review 5.  Association of the ABCB1 C3435T polymorphism with responsiveness to and toxicity of DMARDs in rheumatoid arthritis : A meta-analysis.

Authors:  Y H Lee; S-C Bae; G G Song
Journal:  Z Rheumatol       Date:  2016-09       Impact factor: 1.372

Review 6.  Th17.1 lymphocytes: emerging players in the orchestra of immune-mediated inflammatory diseases.

Authors:  Durga Prasanna Misra; Vikas Agarwal
Journal:  Clin Rheumatol       Date:  2022-05-11       Impact factor: 3.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.